Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | PNP | P00491 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21396498 | 0.71 | ADORA2A (0.48) | RAB9APDE5APDE4APDE4BPDE4C | |
| SCHEMBL21396345 | 0.71 | TDP1 (0.38) | — | |
| SCHEMBL21396533 | 0.70 | — | — | |
| SCHEMBL25933224 | 0.68 | TDP1 (0.42) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25931305 | 0.68 | TDP1 (0.42) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21396468 | 0.67 | PNP (0.33) | PNP | |
| SCHEMBL21396464 | 0.66 | TDP1 (0.39) | ADORA1 | |
| SCHEMBL29727308 | 0.65 | CYP1A2 (0.59) | ADORA2AADORA1PNPCYP1A2LMNA | |
| SCHEMBL25931304 | 0.64 | TDP1 (0.44) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21396461 | 0.63 | PNP (0.35) | PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292214-A1 | NEW EQUATORIALLY MODIFIED POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | MIRECA MEDICINES GMBH (DE) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292214-A1 | NEW EQUATORIALLY MODIFIED POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | PDE7A, PRKG1, PDE4C | RAB9A 4028/4885PDE5A 4/4885PDE4A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.